Press Releases - G1 Therapeutics, Inc.

Press Releases

Date	Title
9/18/24	Pharmacosmos Group and G1 Therapeutics Announce Successful Closing of Tender Offer
9/5/24	Pharmacosmos Group and G1 Therapeutics Announce Expiration of Hart-Scott-Rodino Waiting Period
8/8/24	G1 Therapeutics Provides Second Quarter 2024 Financial Results and Operational Highlights
8/7/24	Pharmacosmos Group to Acquire G1 Therapeutics
8/1/24	G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
7/25/24	G1 Therapeutics to Release Second Quarter 2024 Financial Results and Provide Business Update on August 8, 2024
7/1/24	G1 Therapeutics Added to the Russell 2000® and 3000® Indexes
6/24/24	G1 Therapeutics Provides Update on Phase 3 PRESERVE 2 Trial in Patients Receiving Trilaciclib Prior to First Line Chemotherapy in Metastatic Triple Negative Breast Cancer (mTNBC)
6/5/24	G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
5/28/24	Meaningful Improvement in Overall Survival (OS) and Tolerability Observed in Patients Receiving Trilaciclib in Combination with a TROP2 Antibody-Drug Conjugate (ADC)